Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

C4 Therapeutics, Inc.

NASDAQ: CCCC · Life Sciences · 4 alerts · CIK 1662579

Share price
$2.65Close, Nov 16
Market cap
$348M
Shares outstanding
131.32MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All C4 Therapeutics, Inc. filings on SEC EDGAR ↗

7:05 AM ET 8-K
Clinical Trial Data

C4 Therapeutics Clinical Trial Data

C4 Therapeutics presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and preliminary Phase 1b data for cemsidomide combined with elranatamab at the 23rd International Myeloma Society Annual Meeting. The data demonstrated that cemsidomide drives T-cell activation and prevents T-cell exhaustion, supporting its potential as a combination partner for immune-based therapies in relapsed/refractory multiple myeloma. Additionally, the 75 µg dose level in the Phase 1b trial was declared safe, allowing the study to advance to dose expansion and escalation cohorts.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.